Strategies for the chemical and biological functionalization of scaffolds for cardiac tissue engineering: A review

Journal of the Royal Society Interface

Volumn 12, Issue 108, 2015, Pages

  Tallawi, Marwa ^a   Rosellini, Elisabetta ^b   Barbani, Niccoletta ^b   Grazia Cascone, Maria ^b   Rai, Ranjana ^a   Saint Pierre, Guillaume ^c   Boccaccini, Aldo R ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF PISA   (Italy)

^c Inspiralia Materials Laboratory Campus de Cantoblanco   (Spain)

Author keywords

Biofunctionalization; Biological modification; Biomimetic scaffolds; Cardiac tissue engineering; Chemical modification

Indexed keywords

ACRYLIC MONOMERS; BIOCOMPATIBILITY; BIODEGRADABLE POLYMERS; BIOLOGICAL MATERIALS; BIOMATERIALS; BIOMECHANICS; BIOMIMETICS; CELL ENGINEERING; CELLS; CHEMICAL MODIFICATION; CYTOLOGY; HEART; POLYMERS; TISSUE; TISSUE ENGINEERING;

BIOFUNCTIONALIZATION; BIOLOGICAL MODIFICATION; BIOMIMETIC SCAFFOLDS; CARDIAC TISSUE ENGINEERING; CELL RECOGNITION SITES; CELL-MATERIAL INTERACTION; CHEMICAL AND BIOLOGICALS; POLY (N ISOPROPYLACRYLAMIDE);

SCAFFOLDS (BIOLOGY);

AVIDIN; BIOTIN; COLLAGEN; ERYTHROPOIETIN; FIBRONECTIN; GELATIN; GLYCOSAMINOGLYCAN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HEPARIN; LAMININ; NANOFIBER; NEPHRONECTIN; SCLEROPROTEIN; SOMATOMEDIN; UNCLASSIFIED DRUG; VASCULOTROPIN; BIOMATERIAL;

ADSORPTION; AMINO ACID SEQUENCE; CARDIAC TISSUE ENGINEERING; CELL ADHESION; CELL INTERACTION; CHEMICAL BINDING; CHEMICAL MODIFICATION; ELECTROSPINNING; EXTRACELLULAR MATRIX; HEART; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR IMPRINTING; NONHUMAN; PROTEIN BINDING; REVIEW; TISSUE ENGINEERING; TISSUE SCAFFOLD; ANIMAL; CARDIAC MUSCLE; CHEMISTRY; PROCEDURES;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELL ADHESION; HUMANS; MYOCARDIUM; TISSUE ENGINEERING; TISSUE SCAFFOLDS;

EID: 84936767477     PISSN: 17425689     EISSN: 17425662     Source Type: Journal    
DOI: 10.1098/rsif.2015.0254     Document Type: Review

References (281)

1. Kajstura J et al. 2010 Myocyte turnover in the aging human heart. Circ. Res. 107, 1374-1386. (doi:10. 1161/CIRCRESAHA.110.231498)
2. Improvement P, Goldberg LR. 2010 Heart failure. Ann. Intern. Med. 152, ITC61-15; quiz ITC616.
3. Birks E, Tansley P, Hardy J, George R, Bowles C, Burke M, Banner N, Khaghani A, Yacoub M. 2006 Left ventricular assist device and drug therapy for the reversal of heart failure. N. Engl. J. Med. 335, 1873-1884. (doi:10.1056/NEJMoa053063)
4. Reffelmann T, Kloner RA. 2003 Cellular cardiomyoplasty-cardiomyocytes, skeletal myoblasts, or stem cells for regenerating myocardium and treatment of heart failure? Cardiovasc. Res. 58, 358-368. (doi:10.1016/S0008-6363(02)00739-3)
5. Laflamme M, Murry C. 2005 Regenerating the heart. Nat. Biotechnol. 23, 845-856. (doi:10.1038/nbt1117)
6. Leor J, Amsalem Y, Cohen S. 2005 Cells, scaffolds, and molecules for myocardial tissue engineering. Pharmacol. Ther. 105, 151-163. (doi:10.1016/j. pharmthera.2004.10.003)
7. Chen Q-Z, Harding SE, Ali NN, Lyon AR, Boccaccini AR. 2008 Biomaterials in cardiac tissue engineering: ten years of research survey. Mater. Sci. Eng. R Rep. 59, 1-37. (doi:10.1016/j.mser.2007.08.001)
8. Pons J, Huang Y, Takagawa J, Arakawa-Hoyt J, Ye J, Grossman W, Kan Y, Su H. 2009 Combining angiogenic gene and stem cell therapies for myocardial infarction. J. Gene Med. 11, 743-753. (doi:10.1002/jgm.1362)
9. Akins R. 2002 Can tissue engineering mend broken hearts? Circ. Res. 90, 120-122.
10. Gálvez-Montón C, Prat-Vidal C, Roura S, Soler-Botija C, Bayes-Genis A. 2013 Update: Innovation in cardiology (IV). Cardiac tissue engineering and the bioartificial heart. Rev. Esp. Cardiol. (Engl. Ed). 66, 391-399. (doi:10.1016/j.recesp.2012.11.013)
11. Jawad H, Ali NN, Lyon AR, Chen QZ, Harding SE, Boccaccini AR. 2007 Myocardial tissue engineering: a review. J. Tissue Eng. Regen. Med. 1, 327-342. (doi:10.1002/term.46)
12. Silvestri A, Boffito M, Sartori S, Ciardelli G. 2013 Biomimetic materials and scaffolds for myocardial tissue regeneration. Macromol. Biosci. 13, 984-1019. (doi:10.1002/mabi. 201200483)
13. Giraud M-N, Guex AG, Tevaearai HT. 2012 Cell therapies for heart function recovery: focus on myocardial tissue engineering and nanotechnologies. Cardiol. Res. Pract. 2012, 971614. (doi:10.1155/2012/971614)
14. Rane AA, Christman KL. 2011 Biomaterials for the treatment of myocardial infarction: a 5-year update. J. Am. Coll. Cardiol. 58, 2615-2629. (doi:10.1016/j. jacc.2011.11.001)
15. Jawad H, Lyon A, Harding SE, Ali N, Boccaccini A. 2008 Myocardial tissue engineering. Brit. Med. Bull. 87, 31-47. (doi:10.1093/bmb/ldn026)
16. Bhatia S. 2010 Tissue engineering for clinical applications. Biotechnol. J. 5, 1309-1323. (doi:10. 1002/biot.201000230)
17. Li RK, Jia ZQ, Weisel RD, Mickle DA, Choi A, Yau TM. 1999 Survival and function of bioengineered cardiac grafts. Circulation 100, II63-II69. (doi:10.1161/01. CIR.100.15.e63)
18. Leor J, Aboulafia-Etzion S, Dar A, Shapiro L, Barbash IM, Battler A, Granot Y, Cohen S. 2000 Bioengineered cardiac grafts: a new approach to repair the infarcted myocardium? Circulation 102, III56-III61. (doi:10.1161/01.CIR.102.suppl-3.III-56)
19. Kofidis T, Akhyari P, Wachsmann B, Boublik J, Mueller-Stahl K, Leyh R, Fischer S, Haverich A. 2002 A novel bioartificial myocardial tissue and its prospective use in cardiac surgery. Eur. J. Cardiothoracic Surg. 22, 238-243. (doi:10.1016/S1010-7940(02)00256-7)
20. Zhong Z, Teo WE, Zhu X, Beuerman R, Ramakrishna S, Yung LYL. 2005 Formation of collagen2 glycosaminoglycan blended nanofibrous scaffolds and their biological properties. Biomacromolecules 6, 2998-3004. (doi:10.1021/bm050318p)
21. Dai W, Wold LE, Dow JS, Kloner RA. 2005 Thickening of the infarcted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J. Am. Coll. Cardiol. 46, 714-719. (doi:10.1016/j.jacc.2005.04.056)
22. Christman KL, Vardanian AJ, Fang Q, Sievers RE, Fok HH, Lee RJ. 2004 Injectable fibrin scaffold improves cell transplant survival, reduces infarct expansion, and induces neovasculature formation in ischemic myocardium. J. Am. Coll. Cardiol. 44, 654-660. (doi:10.1016/j.jacc.2004.04.040)
23. Ryu JH et al. 2005 Implantation of bone marrow mononuclear cells using injectable fibrin matrix enhances neovascularization in infarcted myocardium. Biomaterials 26, 319-326. (doi:10. 1016/j.biomaterials.2004.02.058)
24. Grover GN, Rao N, Christman KL. 2014 Myocardial matrix-polyethylene glycol hybrid hydrogels for tissue engineering. Nanotechnology 25, 014011. (doi:10.1088/0957-4484/25/1/014011)
25. Iyer RK, Chiu LLY, Radisic M. 2009 Microfabricated poly(ethylene glycol) templates enable rapid screening of triculture conditions for cardiac tissue engineering. J. Biomed. Mater. Res. A 89, 616-631. (doi:10.1002/jbm.a.32014)
26. Mathieu HJ. 2001 Bioengineered material surfaces for medical applications. Surf. Interface Anal. 32, 3-9. (doi:10.1002/sia.995)
27. Vogler EA, Siedlecki CA. 2009 Contact activation of blood-plasma coagulation. Biomaterials 30, 1857-1869. (doi:10.1016/j.biomaterials.2008.12.041)
28. Von Segesser LK. 1996 Heparin-bonded surfaces in extracorporeal membrane oxygenation for cardiac support. Ann. Thorac. Surg. 61, 330-335. (doi:10.1016/0003-4975(95)01011-4)
29. Bordenave L, Fernandez P, Rémy-Zolghadri M, Villars S, Daculsi R, Midy D. 2005 In vitro endothelialized ePTFE prostheses: clinical update 20 years after the first realization. Clin. Hemorheol. Microcirc. 33, 227-234.
30. Silvestri A, Sartori S, Boffito M, Mattu C, Di Rienzo AM, Boccafoschi F, Ciardelli G. 2014 Biomimetic myocardial patches fabricated with poly(1-caprolactone) and polyethylene glycol-based polyurethanes. J. Biomed. Mater. Res. B, Appl. Biomater. 102, 1002-1013. (doi:10.1002/jbm. b.33081)
31. Guan J, Fujimoto KL, Sacks MS, Wagner WR. 2005 Preparation and characterization of highly porous, biodegradable polyurethane scaffolds for soft tissue applications. Biomaterials 26, 3961-3971. (doi:10. 1016/j.biomaterials.2004.10.018)
32. Tjia J, Aneskievich B, Moghe P. 1999 Substrateadsorbed collagen and cell secreted fibronectin concertedly induce cell migration on poly(lactideglycolide) substrates. Biomaterials 20, 2223-2233. (doi:10.1016/S0142-9612(99)00153-2)
33. Khang G, Lee I, Lee H. 2001 Interaction of cells onto physicochemically treated PLGA surfaces. Tissue Eng. 7, 236.
34. Lavik E, Langer R. 2015 Tissue engineering: current state and perspectives. Appl. Microbiol. Biotechnol. 65, 1-8.
35. Charlotte KW. 2007 Synthesis of functionalized biodegradable polyesters. Chem. Soc. Rev. 36, 1573-1580. (doi:10.1039/b614342n)
36. Lee JW, Serna F, Nickels J, Schmidt CE. 2006 Carboxylic acid-functionalized conductive polypyrrole as a bioactive platform for cell adhesion. Biomacromolecules 7, 1692-1695. (doi:10.1021/bm060220q)
37. Gerhardt W, Noga D, Hardcastle K, García A, Collard D, Weck M. 2006 Functional lactide monomers: methodology and polymerization. Biomacromolecules 7, 1735-1742. (doi:10.1021/bm060024j)
38. Hird B, Eisenberg A. 1993 p-Carboxylation of linear high molecular-mass polystyrene. J. Polym. Sci. A, Polym. Chem. 31, 1377-1381. (doi:10.1002/pola. 1993.080310604)
39. Beltrami AP et al. 2003 Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 114, 763-776. (doi:10.1016/S0092-8674(03)00687-1)
40. Matsuura K et al. 2004 Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J. Biol. Chem. 279, 11 384-11 391. (doi:10.1074/jbc.M310822200)
41. Hench LL, Polak JM. 2002 Third-generation biomedical materials. Science 295, 1014-1017. (doi:10.1126/science.1067404)
42. Hersel U, Dahmen C, Kessler H. 2003 RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 24, 4385-4415. (doi:10. 1016/S0142-9612(03)00343-0)
43. Ruoslahti E. 1996 RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12, 697-715. (doi:10.1146/annurev.cellbio.12. 1.697)
44. Hattori S, Andrade JD, Hibbs JBJ, Gregonis DE, King RN. 1985 Fibroblast cell proliferation on charged hydroxyethyl methacrylate copolymers. J. Colloid Interface Sci. 104, 72-78. (doi:10.1016/0021-9797(85)90010-4)
45. Hildebrand HF P, Rocher P, Monchau F, Delcourt-Debruyne E. 2002 Kollagen - Aufbereitung und Eigenschaften als Biomaterial. Biomaterialien 3, 14-20. (doi:10.1515/BIOMAT.2002.3.1.14)
46. Serpooshan V, Julien M, Nguyen O, Wang H, Li A, Muja N, Henderson JE, Nazhat SN. 2010 Reduced hydraulic permeability of three-dimensional collagen scaffolds attenuates gel contraction and promotes the growth and differentiation of mesenchymal stem cells. Acta Biomater. 6, 3978-3987. (doi:10.1016/j.actbio.2010.04.028)
47. Lee CH, Singla A, Lee Y. 2001 Biomedical applications of collagen. Int. J. Pharm. 221, 1-22. (doi:10.1016/S0378-5173(01)00691-3)
48. Serpooshan V, Muja N, Marelli B, Nazhat SN. 2011 Fibroblast contractility and growth in plastic compressed collagen gel scaffolds with microstructures correlated with hydraulic permeability. J. Biomed. Mater. Res. A 96A, 609-620. (doi:10.1002/jbm.a.33008)
49. Venugopal JR, Prabhakaran MP, Mukherjee S, Ravichandran R, Dan K, Ramakrishna S. 2012 Biomaterial strategies for alleviation of myocardial infarction. J. R. Soc. Interface 9, 20110301. (doi:10. 1098/rsif.2011.0301)
50. Hein S, Schaper J. 2001 The extracellular matrix in normal and diseased myocardium. J. Nucl. Cardiol. 8, 188-196. (doi:10.1067/mnc.2001.113331)
51. Park H, Radisic M, Lim JO, Chang BH, Vunjak-Novakovic G. 2005 A novel composite scaffold for cardiac tissue engineering. Vitr. Cell. Dev. Biol. Anim. 41, 188-196. (doi:10.1290/0411071.1)
52. Bai XP, Zheng HX, Fang R, Wang TR, Hou XL, Li Y, Chen XB, Tian WM. 2011 Fabrication of engineered heart tissue grafts from alginate/collagen barium composite microbeads. Biomed. Mater. 6, 45002. (doi:10.1088/1748-6041/6/4/045002)
53. Hidalgo-Bastida L, Barry J, Everitt N, Rose F, Buttery L, Hall I, Claycomb W, Shakesheff K. 2007 Cell adhesion and mechanical properties of a flexible scaffold for cardiac tissue engineering. Acta Biomater. 3, 457-462. (doi:10.1016/j.actbio.2006. 12.006)
54. Lundgren E, Terracio L, Ma?rdh S, Borg TK. 1985 Extracellular matrix components influence the survival of adult cardiac myocytes in vitro. Exp. Cell Res. 158, 371-381. (doi:10.1016/0014-4827(85)90462-8)
55. Choi S, Hong Y, Lee I, Huh D, Jeon T-J, Kim SM. 2013 Effects of various extracellular matrix proteins on the growth of HL-1 cardiomyocytes. Cells Tissues Organs 198, 349-356. (doi:10.1159/000358755)
56. Battista S et al. 2005 The effect of matrix composition of 3D constructs on embryonic stem cell differentiation. Biomaterials 26, 6194-6207. (doi:10.1016/j.biomaterials.2005.04.003)
57. Santiago L, Nowak R, Peter Rubin J, Marra K. 2006 Peptide-surface modification of poly(caprolactone) with laminin-derived sequences for adipose-derived stem cell applications. Biomaterials 27, 2962-2969. (doi:10.1016/j.biomaterials.2006.01.011)
58. Genové E, Shen C, Zhang S, Semino C. 2005 The effect of functionalized self-assembling peptide scaffolds on human aortic endothelial cell function. Biomaterials 26, 3341-3351. (doi:10.1016/j. biomaterials.2004.08.012)
59. Ocalan M, Goodman S, Kühl U, Hauschka S, Von der Mark K. 1988 Laminin alters cell shape and stimulates motility and proliferation of murine skeletal myoblasts. Dev. Biol. 125, 158-167. (doi:10.1016/0012-1606(88)90068-1)
60. Baharvand H, Azarnia M, Parivar K, Ashtiani S. 2005 The effect of extracellular matrix on embryonic stem cell-derived cardiomyocytes. J. Mol. Cell. Cardiol. 38, 495-503. (doi:10.1016/j.yjmcc.2004.12.011)
61. McDevitt T, Angello J, Whitney M, Reinecke H, Hauschka S, Murry C, Stayton P. 2002 In vitro generation of differentiated cardiac myofibers on micropatterned laminin surfaces. J. Biomed. Mater. Res. 60, 472-479. (doi:10.1002/jbm.1292)
62. Chiono V et al. 2014 Polyurethane-based scaffolds for myocardial tissue engineering. Interface Focus 4, 20130045. (doi:10.1098/rsfs.2013.0045)
63. McDevitt T, Woodhouse K, Hauschka S, Murry C, Stayton P. 2003 Spatially organized layers of cardiomyocytes on biodegradable polyurethane films for myocardial repair. J. Biomed. Mater. Res. A 66, 586-595. (doi:10.1002/jbm.a.10504)
64. Alperin C, Zandstra P, Woodhouse K. 2005 Polyurethane films seeded with embryonic stem cell-derived cardiomyocytes for use in cardiac tissue engineering applications. Biomaterials 26, 7377-7386. (doi:10.1016/j.biomaterials.2005.05.064)
65. LaNasa S, Bryant S. 2009 Influence of ECM proteins and their analogs on cells cultured on 2-D hydrogels for cardiac muscle tissue engineering. Acta Biomater. 5, 2929-2938. (doi:10.1016/j.actbio. 2009.05.011)
66. Brandenberger R, Schmidt A, Linton J, Wang D, Backus C, Denda S, Müller U, Reichardt LF. 2001 Identification and characterization of a novel extracellular matrix protein nephronectin that is associated with integrin a8b1 in the embryonic kidney. J. Cell Biol. 154, 447-458. (doi:10.1083/jcb. 200103069)
67. Patra C, Diehl F, Ferrazzi F, van Amerongen MJ, Novoyatleva T, Schaefer L, Muhlfeld C, Jungblut B, Engel FB. 2011 Nephronectin regulates atrioventricular canal differentiation via Bmp4-Has2 signaling in zebrafish. Development 138, 4499-4509. (doi:10.1242/dev.067454)
68. Patra C, Ricciardi F, Engel F. 2012 The functional properties of nephronectin: an adhesion molecule for cardiac tissue engineering. Biomaterials 33, 4327-4335. (doi:10.1016/j.biomaterials.2012.03.021)
69. Datta A, Ghosh AK, Kundu SC. 2001 Differential expression of the fibroin gene in developmental stages of silkworm, Antheraea mylitta (Saturniidae). Comp. Biochem. Physiol. B, Biochem. Mol. Biol. 129, 197-204. (doi:10.1016/S1096-4959(01)00377-3)
70. Cameron VA, Ellmers LJ. 2003 Minireview: Natriuretic peptides during development of the fetal heart and circulation. Endocrinology 144, 2191-2194.
71. Eppenberger-Eberhardt M, Flamme I, Kurer V, Eppenberger HM. 1990 Reexpression of alphasmooth muscle actin isoform in cultured adult rat cardiomyocytes. Dev. Biol. 139, 269-278. (doi:10. 1016/0012-1606(90)90296-U)
72. Van Bilsen M, Chien KR. 1993 Growth and hypertrophy of the heart: towards an understanding of cardiac specific and inducible gene expression. Cardiovasc. Res. 27, 1140-1149. (doi:10.1093/cvr/27.7.1140)
73. Schaub MC, Hefti MA, Harder BA, Eppenberger HM. 1997 Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes. J. Mol. Med. 75, 901-920. (doi:10.1007/s001090050182)
74. Heydarkhan-Hagvall S, Schenke-Layland K, Dhanasopon AP, Rofail F, Smith H, Wu BM, Shemin R, Beygui RE, MacLellan WR. 2008 Threedimensional electrospun ECM-based hybrid scaffolds for cardiovascular tissue engineering. Biomaterials 29, 2907-2914. (doi:10.1016/j.biomaterials.2008. 03.034)
75. Zhang S, Huang Y, Yang X, Mei F, Ma Q, Chen G, Ryu S, Deng X. 2009 Gelatin nanofibrous membrane fabricated by electrospinning of aqueous gelatin solution for guided tissue regeneration. J. Biomed. Mater. Res. A 90, 671-679. (doi:10.1002/jbm.a.32136)
76. Zhang Y, Ouyang H, Chwee TL, Ramakrishna S, Huang ZM. 2005 Electrospinning of gelatin fibers and gelatin/PCL composite fibrous scaffolds. J. Biomed. Mater. Res. B Appl. Biomater. 72, 156-165. (doi:10.1002/jbm.b.30128)
77. Miskon A, Ehashi T, Mahara A, Uyama H, Yamaoka T. 2009 Beating behavior of primary neonatal cardiomyocytes and cardiac-differentiated P19.CL6 cells on different extracellular matrix components. J. Artif. Organs 12, 111-117. (doi:10. 1007/s10047-009-0449-4)
78. Lanza R, Langer R, Vacanti JP. 2011 Principles of tissue engineering. San Diego, CA: Academic Press.
79. Pierschbacher M, Ruoslahti E. 1984 Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature 309, 30-33. (doi:10.1038/309030a0)
80. Boateng S, Lateef S, Mosley W, Hartman T, Hanley L, Russell B. 2005 RGD and YIGSR synthetic peptides facilitate cellular adhesion identical to that of laminin and fibronectin but alter the physiology of neonatal cardiac myocytes. Am. J. Physiol. Cell Physiol. 288, C30-C38.
81. Yeo Y, Geng W, Ito T, Kohane D, Burdick J, Radisic M. 2007 Photocrosslinkable hydrogel for myocyte cell culture and injection. J. Biomed. Mater. Res. B Appl. Biomater. 81, 312-322. (doi:10.1002/jbm.b.30667)
82. Sondermeijer H, See F, Seki T, Witkowski P, Woodland D, Hardy M. 2008 Biocompatible 3-dimensional RGD-modified alginate scaffold designed to enhance cell transplantation to infarcted myocardium. Circulation 118, S322.
83. Gandaglia A et al. 2012 Cardiomyocytes in vitro adhesion is actively influenced by biomimetic synthetic peptides for cardiac tissue engineering. Tissue Eng. A 18, 725-736. (doi:10.1089/ten.tea. 2011.0254)
84. Tsur-Gang O, Ruvinov E, Landa N, Holbova R, Feinberg M, Leor J, Cohen S. 2009 The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction. Biomaterials 30, 189-195. (doi:10.1016/j.biomaterials.2008.09.018)
85. Yu J, Gu Y, Du K, Mihardja S, Sievers R, Lee R. 2009 The effect of injected RGD modified alginate on angiogenesis and left ventricular function in a chronic rat infarct model. Biomaterials 30, 751-756. (doi:10.1016/j.biomaterials.2008.09.059)
86. Schussler O et al. 2009 Use of arginine-glycine-aspartic acid adhesion peptides coupled with a new collagen scaffold to engineer a myocardium-like tissue graft. Nat. Clin. Pr. Cardiovasc. Med. 6, 240-249. (doi:10.1038/ncpcardio1451)
87. Yu J, Du K, Fang Q, Gu Y, Mihardja S, Sievers R, Wu J, Lee R. 2010 The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat. Biomaterials 31, 7012-7020. (doi:10. 1016/j.biomaterials.2010.05.078)
88. Shachar M, Tsur-Gang O, Dvir T, Leor JCS, Shachar M, Tsur-Gang O, Dvir T, Leor J, Cohen S. 2011 The effect of immobilized RGD peptide in alginate scaffolds on cardiac tissue engineering. Acta Biomater. 7, 152-162. (doi:10.1016/j.actbio.2010.07.034)
89. Sapir Y, Kryukov O, Cohen S. 2011 Integration of multiple cell-matrix interactions into alginate scaffolds for promoting cardiac tissue regeneration. Biomaterials 32, 1838-1847. (doi:10.1016/j. biomaterials.2010.11.008)
90. Maitra N, Flink I, Bahl J, Morkin E. 2000 Expression of alpha and beta integrins during terminal differentiation of cardiomyocytes. Cardiovasc. Res. 47, 715-725. (doi:10.1016/S0008-6363 (00)00140-1)
91. Ross R, Borg T. 2001 Integrins and the myocardium. Circ. Res. 88, 1112-1119. (doi:10.1161/hh1101. 091862)
92. Kraehenbuehl T, Zammaretti P, Van der Vlies A, Schoenmakers R, Lutolf M, Jaconi M, Hubbell J. 2008 Three-dimensional extracellular matrixdirected cardioprogenitor differentiation: systematic modulation of a synthetic cell-responsive PEGhydrogel. Biomaterials 29, 2757-2766. (doi:10. 1016/j.biomaterials.2008.03.016)
93. Bauer S, Bauer R, Liu Z, Chen H, Goldstein L, Velazquez O. 2005 Vascular endothelial growth factor-C promotes vasculogenesis, angiogenesis, and collagen constriction in three-dimensional collagen gels. J. Vasc. Surg. 41, 699-707. (doi:10.1016/j.jvs. 2005.01.015)
94. Zisch AH et al. 2003 Cell-demanded release of VEGF from synthetic, biointeractive cell ingrowth matrices for vascularized tissue growth. FASEB J. 17, 2260-2262. (doi:10.1096/fj.02-1041fje)
95. Zisch A, Lutolf M, Hubbell J. 2003 Biopolymeric delivery matrices for angiogenic growth factors. Cardiovasc. Pathol. 12, 295-310. (doi:10.1016/S1054-8807(03)00089-9)
96. Huang Y, Kaigler D, Rice K, Krebsbach P, Mooney D. 2005 Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. J. Bone Min. Res. 20, 848-857. (doi:10.1359/JBMR.041226)
97. Marra K, Defail A, Clavijo-Alvarez J, Badylak S, Taieb A, Schipper B, Bennett J, Rubin J. 2008 FGF-2 enhances vascularization for adipose tissue engineering. Plast. Reconstr. Surg. 121, 1153-1164. (doi:10.1097/01.prs.0000305517.93747.72)
98. Lin H, Chen B, Sun W, Zhao W, Zhao Y, Dai J. 2006 The effect of collagen-targeting platelet-derived growth factor on cellularization and vascularization of collagen scaffolds. Biomaterials 27, 5708-5714. (doi:10.1016/j.biomaterials.2006.07.023)
99. Zhao W et al. 2008 Improved neovascularization and wound repair by targeting human basic fibroblast growth factor (bFGF) to fibrin. J. Mol. Med. 86, 1127-1138. (doi:10.1007/s00109-008-0372-9)
100. Elçin Y, Dixit V, Gitnick G. 2001 Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: implications for tissue engineering and wound healing. Artif. Organs 25, 558-565. (doi:10.1046/j.1525-1594. 2001.025007558.x)
101. Andrae J, Gallini R, Betsholtz C. 2008 Role of plateletderived growth factors in physiology and medicine. Genes Dev. 22, 1276-1312. (doi:10. 1101/gad.1653708)
102. Perets A, Baruch Y, Weisbuch F, Shoshany G, Neufeld G, Cohen S. 2003 Enhancing the vascularization of three-dimensional porous alginate scaffolds by incorporating controlled release basic fibroblast growth factor microspheres. J. Biomed Mater. Res. A 65, 489-497. (doi:10.1002/jbm. a.10542)
103. Nian M, Lee P, Khaper N, Peter L. 2004 Inflammatory cytokines and postmyocardial infarction remodeling. Circ. Res. 94, 1543-1553. (doi:10.1161/01.RES.0000130526.20854.fa)
104. Minatoguchi S et al. 2004 Acceleration of the healing process and myocardial regeneration may be important as a mechanism of improvement of cardiac function and remodeling by postinfarction granulocyte colony-stimulating factor treatment. Circulation 109, 2572-2580. (doi:10.1161/01.CIR. 0000129770.93985.3E)
105. Takano H, Ohtsuka M, Akazawa H, Toko H, Harada M, Hasegawa H, Nagai T, Komuro I. 2003 Pleiotropic effects of cytokines on acute myocardial infarction: G-CSF as a novel therapy for acute myocardial infarction. Curr. Pharm. 9, 1121-1127. (doi:10. 2174/1381612033455008)
106. Hiasa K et al. 2004 Gene transfer of stromal cellderived factor-1a enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation 109, 2454-2461. (doi:10.1161/01.CIR.0000128213. 96779.61)
107. Zou Y et al. 2003 Leukemia inhibitory factor enhances survival of cardiomyocytes and induces regeneration of myocardium after myocardial infarction. Circulation 108, 748-753. (doi:10.1161/01.CIR.0000081773.76337.44)
108. Musarò A et al. 2004 Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc. Natl Acad. Sci. USA 101, 1206-1210. (doi:10.1073/pnas. 0303792101)
109. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M. 2003 Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl Acad. Sci. USA 100, 4802-4806. (doi:10.1073/pnas. 0630444100)
110. Ladoux A, Frelin C. 1993 Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. Biochem. Biophys. Res. Commun. 195, 1005-1010. (doi:10.1006/bbrc. 1993.2144)
111. Maruyama K et al. 1999 Interleukin-1 b upregulates cardiac expression of vascular endothelial growth factor and its receptor KDR/flk-1 via activation of protein tyrosine kinases. J. Mol. Cell Cardiol. 31, 607-617. (doi:10.1006/jmcc.1998.0895)
112. Chintalgattu V, Nair D, Katwa L. 2003 Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J. Mol. Cell Cardiol. 35, 277-286. (doi:10.1016/S0022-2828(03)00006-3)
113. Koblizek T, Weiss C, Yancopoulos G, Deutsch U, Risau W. 1998 Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr. Biol. 8, 529-532. (doi:10.1016/S0960-9822(98)70205-2)
114. Kutryk MJB, Stewart DJ. 2003 Angiogenesis of the heart. Microsc. Res. Technol. 60, 138-158. (doi:10. 1002/jemt.10252)
115. Ozawa CR, Banfi A, Glazer NL, Thurston G, Springer ML, Kraft PE, McDonald DM, Blau HM. 2004 Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest. 113, 516-527. (doi:10.1172/JCI18420)
116. Ohtsuka M et al. 2004 Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization. FASEB J. 18, 851-853. (doi:10.1096/fj.03-0637fje)
117. Orlic D et al. 2001 Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl Acad. Sci. USA 98, 10344-10349. (doi:10.1073/pnas.181177898)
118. Torella D et al. 2004 Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression. Circ. Res. 94, 514-524. (doi:10. 1161/01.RES.0000117306.10142.50)
119. Winn N, Paul A, Musaró A, Rosenthal N. 2002 Insulin-like growth factor isoforms in skeletal muscle aging, regeneration, and disease. Cold Spring Harb. Symp. Quant. Biol. 67, 507-518. (doi:10. 1101/sqb.2002.67.507)
120. Ito Y. 2008 Covalently immobilized biosignal molecule materials for tissue engineering. Soft Matter 4, 46-56. (doi:10.1039/B708359A)
121. Shen Y, Shoichet M, Radisic M. 2008 Vascular endothelial growth factor immobilized in collagen scaffold promotes penetration and proliferation of endothelial cells. Acta Biomater. 4, 477-489. (doi:10.1016/j.actbio.2007.12.011)
122. Losi P et al. 2010 Tissue response to poly(ether)urethane-polydimethylsiloxane-fibrin composite scaffolds for controlled delivery of pro-angiogenic growth factors. Biomaterials 31, 5336-5344. (doi:10.1016/j.biomaterials.2010. 03.033)
123. Tengood J, Kovach K, Vescovi P, Russell A, Little S. 2010 Sequential delivery of vascular endothelial growth factor and sphingosine 1-phosphate for angiogenesis. Biomaterials 31, 7805-7812. (doi:10. 1016/j.biomaterials.2010.07.010)
124. Chiu L, Radisic M. 2010 Scaffolds with covalently immobilized VEGF and angiopoietin-1 for vascularization of engineered tissues. Biomaterials 31, 226-241. (doi:10.1016/j.biomaterials.2009. 09.039)
125. Amsden B, Timbart L, Marecak D, Chapanian R, Tse M, Pang S. 2010 VEGF-induced angiogenesis following localized delivery via injectable, low viscosity poly(trimethylene carbonate). J. Control Release 145, 109-115. (doi:10.1016/j.jconrel. 2010.03.029)
126. Chapanian R, Amsden B. 2010 Combined and sequential delivery of bioactive VEGF165 and HGF from poly(trimethylene carbonate) based photo-cross-linked elastomers. J. Control Release. 143, 53-63. (doi:10.1016/j.jconrel.2009. 11.025)
127. Jia X et al. 2011 Sustained release of VEGF by coaxial electrospun dextran/PLGA fibrous membranes in vascular tissue engineering. J. Biomater. Sci. Polym. Ed. 22, 1811-1827. (doi:10. 1163/092050610X528534)
128. Silva E, Mooney D. 2010 Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 31, 1235-1241. (doi:10.1016/j. biomaterials.2009.10.052)
129. Zieris A, Prokoph S, Levental K, Welzel P, Grimmer M, Freudenberg U, Werner C. 2010 FGF-2 and VEGF functionalization of starPEG-heparin hydrogels to modulate biomolecular and physical cues of angiogenesis. Biomaterials 31, 7985-7994. (doi:10. 1016/j.biomaterials.2010.07.021)
130. Zieris A, Chwalek K, Prokoph S, Levental K, Welzel P, Freudenberg U, Werner C. 2011 Dual independent delivery of pro-angiogenic growth factors from starPEG-heparin hydrogels. J. Control Release 156, 28-36. (doi:10.1016/j.jconrel.2011.06.042)
131. Miyagi Y, Chiu L, Cimini M, Weisel R, Radisic M, Li R. 2010 Biodegradable collagen patch with covalently immobilized VEGF for myocardial repair. Biomaterials 32, 1280-1290. (doi:10.1016/j. biomaterials.2010.10.007)
132. Porter A, Klinge C, Gobin A. 2011 Biomimetic hydrogels with VEGF induce angiogenic processes in both hUVEC and hMEC. Biomacromolecules 12, 242-246. (doi:10.1021/bm101220b)
133. Singh S, Wu B, Dunn J. 2011 The enhancement of VEGF-mediated angiogenesis by polycaprolactone scaffolds with surface cross-linked heparin. Biomaterials 32, 2059-2069. (doi:10.1016/j. biomaterials.2010.11.038)
134. Wu J, Zeng F, Huang X, Chung J, Konecny F, Weisel R, Li R. 2011 Infarct stabilization and cardiac repair with a VEGF-conjugated, injectable hydrogel. Biomaterials 32, 579-586. (doi:10.1016/j. biomaterials.2010.08.098)
135. Gao J, Liu J, Gao Y, Wang C, Zhao Y, Chen B, Xiao Z, Miao Q, Dai J. 2011 A myocardial patch made of collagen membranes loaded with collagen-binding human vascular endothelial growth factor accelerates healing of the injured rabbit heart. Tissue Eng. A 17, 2739-2747. (doi:10.1089/ten.tea. 2011.0105)
136. Garbern J, Minami E, Stayton P, Murry C. 2011 Delivery of basic fibroblast growth factor with a pH-responsive, injectable hydrogel to improve angiogenesis in infarcted myocardium. Biomaterials 32, 2407-2416. (doi:10.1016/j.biomaterials.2010. 11.075)
137. Wang T, Jiang X, Lin T, Ren S, Li X, Zhang X, Tang Q. 2009 The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel. Biomaterials 30, 4161-4167. (doi:10.1016/j.biomaterials.2009. 04.033)
138. Spadaccio C et al. 2011 A G-CSF functionalized scaffold for stem cells seeding: a differentiating device for cardiac purposes. J. Cell. Mol. Med. 15, 1096-1108. (doi:10.1111/j.1582-4934.2010. 01100.x)
139. Fiedler U, Augustin H. 2006 Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 27, 552-558. (doi:10.1016/j.it.2006. 10.004)
140. Thurston G, Suri C, Smith K, McClain J, Sato T, Yancopoulos G, McDonald D. 1999 Leakageresistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science (80-.). 286, 2511-2514. (doi:10.1126/science.286.5449. 2511)
141. Epstein S, Kornowski R, Fuchs S, Dvorak H. 2001 Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation. 104, 115-119. (doi:10.1161/01.CIR. 104.1.115)
142. Peters M, Isenberg B, Rowley J, Mooney D. 1998 Release from alginate enhances the biological activity of vascular endothelial growth factor. J. Biomater. Sci. Polym. Ed. 9, 1267-1278. (doi:10. 1163/156856298X00389)
143. Xu C, Police S, Rao N, Carpenter M. 2002 Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ. Res. 91, 501-508. (doi:10.1161/01.RES.0000035254. 80718.91)
144. Fukuda K. 2001 Development of regenerative cardiomyocytes from mesenchymal stem cells for cardiovascular tissue engineering. Artif Organs. 25, 187-193. (doi:10.1046/j.1525-1594.2001. 025003187.x)
145. Fukuda K. 2002 Reprogramming of bone marrow mesenchymal stem cells into cardiomyocytes. C. R. Biol. 325, 1027-1038. (doi:10.1016/S1631-0691(02)01524-X)
146. Fukuda K. 2003 Use of adult marrow mesenchymal stem cells for regeneration of cardiomyocytes. Bone Marrow Transplant. 32, S25-S27. (doi:10.1038/sj. bmt.1703940)
147. Hakuno D et al. 2002 Bone marrow-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors. Circulation 105, 380-386. (doi:10.1161/hc0302. 102593)
148. Rangappa S, Fen C, Lee E, Bongso A, Sim E. 2003 Transformation of adult mesenchymal stem cells isolated from the fatty tissue into cardiomyocytes. Ann. Thorac. Surg. 75, 775-779. (doi:10.1016/S0003-4975(02)04568-X)
149. Wobus AM et al. 2014 Retinoic acid accelerates embryonic stem cell-derived cardiac differentiation and enhances development of ventricular cardiomyocytes. J. Mol. Cell. Cardiol. 29, 1525-1539. (doi:10.1006/jmcc.1997.0433)
150. Takahashi T, Lord B, Schulze PC, Fryer RM, Sarang SS, Gullans SR, Lee RT. 2003 Ascorbic acid enhances differentiation of embryonic stem cells into cardiac myocytes. Circulation 107, 1912-1916. (doi:10. 1161/01.CIR.0000064899.53876.A3)
151. Ventura C, Maioli M. 2000 Opioid peptide gene expression primes cardiogenesis in embryonal pluripotent stem cells. Circ. Res. 87, 189-194. (doi:10.1161/01.RES.87.3.189)
152. McBurney MW, Jones-Villeneuve EM, Edwards MK, Anderson PJ. 1982 Control of muscle and neuronal differentiation in a cultured embryonal carcinoma cell line. Nature 299, 165-167. (doi:10.1038/299165a0)
153. Skerjanc IS, Petropoulos H, Ridgeway AG, Wilton S. 1998 Myocyte enhancer factor 2C and Nkx2-5 up-regulate each other's expression and initiate cardiomyogenesis in P19 Cells. J. Biol. Chem. 273, 34 904-34910. (doi:10.1074/jbc.273.52. 34904)
154. Jiao Y-PY, Cui F-ZF. 2007 Surface modification of polyester biomaterials for tissue engineering. Biomed. Mater. 2, R24-R37. (doi:10.1088/1748-6041/2/4/R02)
155. Oh SH, Lee JH. 2013 Hydrophilization of synthetic biodegradable polymer scaffolds for improved cell/tissue compatibility. Biomed. Mater. 8, 14101. (doi:10.1088/1748-6041/8/1/014101)
156. Croll T, O'Connor A, Stevens G, Cooper-White J. 2004 Controllable surface modification of poly(lactic-coglycolic acid) (PLGA) by hydrolysis or aminolysis: I. Physical, chemical, and theoretical aspects. Biomacromolecules 5, 463-473. (doi:10.1021/bm0343040)
157. Cao Y, Croll T, Cooper-White J, O' Connor A, Stevens G. 2004 Production and surface modification of polylactide-based polymeric scaffolds for soft-tissue engineering. In Biopolymer methods in tissue engineering, vol. 238 (eds A Hollander, P Hatton), pp. 87-111. New York, NY: Humana Press.
158. Chen J, Chu B, Hsiao B. 2006 Mineralization of hydroxyapatite in electrospun nanofibrous poly(L-lactic acid) scaffolds. J. Biomed. Mater. Res. A 79A, 307-317. (doi:10.1002/jbm.a.30799)
159. Yu H, Jang J, Kim T, Lee H, Kim H. 2009 Apatitemineralized polycaprolactone nanofibrous web as a bone tissue regeneration substrate. J. Biomed. Mater. Res. A 88A, 747-754. (doi:10.1002/jbm.a.31709)
160. Nisbet D, Yu L, Zahir T, Forsythe J, Shoichet M. 2008 Characterization of neural stem cells on electrospun poly(1-caprolactone) submicron scaffolds: evaluating their potential in neural tissue engineering. J. Biomater. Sci. Polym. Ed. 19, 623-634. (doi:10.1163/156856208784089652)
161. Zhu Y, Leong M, Ong W, Chan-Park M, Chian K. 2007 Esophageal epithelium regeneration on fibronectin grafted poly(L-lactide-co-caprolactone) (PLLC) nanofiber scaffold. Biomaterials 28, 861-868. (doi:10.1016/j.biomaterials.2006.09.051)
162. Yamagishi H, Crivello JV, Belfort G. 1995 Evaluation of photochemically modified poly(arylsulfone) ultrafiltration membranes. J. Memb. Sci. 105, 249-259. (doi:10.1016/0376-7388(95)00064-J)
163. Janorkar AV, Proulx SE, Metters AT, Hirt DE. 2006 Surface-confined photopolymerization of single- and mixed-monomer systems to tailor the wettability of poly(L-lactide) film. J. Polym. Sci. A, Polym. Chem. 44, 6534-6543. (doi:10.1002/pola.21700)
164. Kubies D, Machová L, Brynda E, Lukáš J, Rypáček F. 2003 Functionalized surfaces of polylactide modified by Langmuir-Blodgett films of amphiphilic block copolymers. J. Mater. Sci. Mater. Med. 14, 143-149. (doi:10.1023/A:1022019813078)
165. Chu P. 2002 Plasma-surface modification of biomaterials. Mater. Sci. Eng. R Rep. 36, 143-206. (doi:10.1016/S0927-796X(02)00004-9)
166. Inagaki N, Narushima K, Lim S. 2003 Effects of aromatic groups in polymer chains on plasma surface modification. J. Appl. Polym. Sci. 89, 96-103. (doi:10.1002/app.12160)
167. Wan Y, Qu X, Lu J, Zhu C, Wan L, Yang J, Bei J, Wang S. 2004 Characterization of surface property of poly(lactide-co-glycolide) after oxygen plasma treatment. Biomaterials 25, 4777-4783. (doi:10. 1016/j.biomaterials.2003.11.051)
168. Barry JJA, Howard D, Shakesheff KM, Howdle SM, Alexander MR. 2006 Using a core-sheath distribution of surface chemistry through 3D tissue engineering scaffolds to control cell ingress. Adv. Mater. 18, 1406-1410. (doi:10.1002/adma. 200502719)
169. Morent R, De Geyter N, Desmet T, Dubruel P, Leys C. 2011 Plasma surface modification of biodegradable polymers: a review. Plasma Process. Polym. 8, 171-190. (doi:10.1002/ppap.201000153)
170. Park K, Ju Y, Son J, Ahn K, Han D. 2007 Surface modification of biodegradable electrospun nanofiber scaffolds and their interaction with fibroblasts. J. Biomater. Sci. Polym. Ed. 18, 369-382. (doi:10. 1163/156856207780424997)
171. Brown DA, Beygui RE, MacLellan WR, Laks H, Dunn JCY, Wu BM. 2005 Modulation of gene expression in neonatal rat cardiomyocytes by surface modification of polylactide-co-glycolide substrates. J. Biomed. Mater. Res. A 74, 419-429. (doi:10.1002/jbm.a. 30344)
172. Tay CY, Yu H, Pal M, Leong WS, Tan NS, Ng KW, Leong DT, Tan LP. 2010 Micropatterned matrix directs differentiation of human mesenchymal stem cells towards myocardial lineage. Exp. Cell Res. 316, 1159-1168. (doi:10.1016/j.yexcr.2010.02.010)
173. Koh H, Yong T, Chan C, Ramakrishna S. 2008 Enhancement of neurite outgrowth using nanostructured scaffolds coupled with laminin. Biomaterials 29, 3574-3582. (doi:10.1016/j. biomaterials.2008.05.014)
174. Ma Z, He W, Yong T, Ramakrishna S. 2005 Grafting of gelatin on electrospun poly(caprolactone) nanofibers to improve endothelial cell spreading and proliferation and to control cell orientation. Tissue Eng. 11, 1149-1158. (doi:10.1089/ten.2005. 11.1149)
175. Casper C, Yang W, Farach-Carson M, Rabolt J. 2007 Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding. Biomacromolecules 8, 1116-1123. (doi:10. 1021/bm061003s)
176. Duan Y, Wang Z, Yan W, Wang S, Zhang S, Jia J. 2007 Preparation of collagen-coated electrospun nanofibers by remote plasma treatment and their biological properties. J. Biomater. Sci. Polym. Ed. 18, 1153-1164. (doi:10.1163/156856207781554019)
177. Lee K, Yoon K, Woo S, Choi I. 2003 Surface modification of poly(glycolic acid) (PGA) for biomedical applications. J. Pharm. Sci. 92, 933-937. (doi:10.1002/jps.10556)
178. Patel S, Kurpinski K, Quigley R, Gao H, Hsiao B, Poo M, Li S. 2007 Bioactive nanofibers: synergistic effects of nanotopography and chemical signaling on cell guidance. Nano Lett 7, 2122-2128. (doi:10. 1021/nl071182z)
179. Chua K, Chai C, Lee P, Ramakrishna S, Leong K, Mao H. 2007 Functional nanofiber scaffolds with different spacers modulate adhesion and expansion of cryopreserved umbilical cord blood hematopoietic stem/progenitor cells. Exp. Hematol. 35, 771-781. (doi:10.1016/j.exphem.2007.02.002)
180. Lee S, Hsiue G, Chang P, Kao C. 1996 Plasmainduced graftedpolymerization of acrylic acid and subsequent grafting of collagen onto polymer film as biomaterials. Biomaterials 17, 1599-1608. (doi:10.1016/0142-9612(95)00316-9)
181. Bakowsky U, Schumacher G, Gege C, Schmidt R, Rothe U, Bendas G. 2002 Cooperation between lateral ligand mobility and accessibility for receptor recognition in selectin-induced cell rolling. Biochemistry 41, 4704-4712. (doi:10.1021/bi0117596)
182. Houseman B, Mrksich M. 2001 The microenvironment of immobilized Arg-Gly-ASP peptides is an important determinant of cell adhesion. Biomaterials 22, 943-955. (doi:10.1016/S0142-9612(00)00259-3)
183. Silva A, Richard C, Bessodes M, Scherman D, Merten O. 2009 Growth factor delivery approaches in hydrogels. Biomacromolecules 10, 9-18. (doi:10. 1021/bm801103c)
184. Tessmar J, Göpferich A. 2007 Matrices and scaffolds for protein delivery in tissue engineering. Adv. Drug Deliv. Rev. 59, 274-291. (doi:10.1016/j.addr.2007. 03.020)
185. Fan V, Tamama K, Au A, Littrell R, Richardson L, Wright J, Wells A, Griffith L. 2007 Tethered epidermal growth factor provides a survival advantage to mesenchymal stem cells. Stem Cells 25, 1241-1251. (doi:10.1634/stemcells.2006-0320)
186. Koch S, Yao C, Grieb G, Prével P, Noah E, Steffens G. 2006 Enhancing angiogenesis in collagen matrices by covalent incorporation of VEGF. J. Mater. Sci. Mater. Med. 17, 735-741. (doi:10.1007/s10856-006-9684-x)
187. Backer M, Patel V, Jehning B, Claffey K, Backer J. 2006 Surface immobilization of active vascular endothelial growth factor via a cysteine-containing tag. Biomaterials 27, 5452-5458. (doi:10.1016/j. biomaterials.2006.06.025)
188. Taguchi T, Kishida A, Akashi M, Maruyama I. 2000 Immobilization of human vascular endothelial growth factor (VEGF165) onto biomaterials: an evaluation of the biological activity of immobilized VEGF165. J. Bioact. Compat. Polym. 15, 309-320. (doi:10.1106/U857-BGYG-UP8G-C6T3)
189. Chiu LLY, Weisel RD, Li R-K, Radisic M, Chiu L, LY WRD, Li R-K. 2011 Defining conditions for covalent immobilization of angiogenic growth factors onto scaffolds for tissue engineering. J. Tissue Eng. Regen. Med. 5, 69-84. (doi:10.1002/term.292)
190. Hlady V, Buijs J. 1996 Protein adsorption on solid surfaces. Curr. Opin. Biotechnol. 7, 72-77. (doi:10. 1016/S0958-1669(96)80098-X)
191. Vogler EA. 2012 Protein adsorption in three dimensions. Biomaterials 33, 1201-1237. (doi:10. 1016/j.biomaterials.2011.10.059)
192. Park H, Temenoff JS, Tabata Y, Caplan AI, Mikos AG. 2007 Injectable biodegradable hydrogel composites for rabbit marrow mesenchymal stem cell and growth factor delivery for cartilage tissue engineering. Biomaterials 28, 3217-3227. (doi:10. 1016/j.biomaterials.2007.03.030)
193. Li B, Davidson JM, Guelcher SA. 2009 The effect of the local delivery of platelet-derived growth factor from reactive two-component polyurethane scaffolds on the healing in rat skin excisional wounds. Biomaterials 30, 3486-3494. (doi:10. 1016/j.biomaterials.2009.03.008)
194. Liu X, Won Y, Ma P. 2005 Surface modification of interconnected porous scaffolds. J. Biomed. Mater. Res. A 74, 84-91. (doi:10.1002/jbm.a.30367)
195. Park H, Temenoff JS, Holland TA, Tabata Y, Mikos AG. 2005 Delivery of TGF-b1 and chondrocytes via injectable, biodegradable hydrogels for cartilage tissue engineering applications. Biomaterials 26, 7095-7103. (doi:10.1016/j.biomaterials.2005.05.083)
196. Taipale J, Keski-Oja J. 1997 Growth factors in the extracellular matrix. FASEB J. 11, 51-59.
197. Sivagnanam V, Song B, Vandevyver C, Gijs MAM. 2009 On-chip immunoassay using electrostatic assembly of streptavidin-coated bead micropatterns. Anal. Chem. 81, 6509-6515. (doi:10.1021/ac9009319)
198. Kim D, Karns K, Tia SQ, He M, Herr AE. 2012 Electrostatic protein immobilization using charged polyacrylamide gels and cationic detergent microfluidic western blotting. Anal. Chem. 84, 2533-2540. (doi:10.1021/ac3000013)
199. Bishop JR, Schuksz M, Esko JD. 2007 Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446, 1030-1037. (doi:10.1038/nature05817)
200. Gama CI, Tully SE, Sotogaku N, Clark PM, Rawat M, Vaidehi N, Goddard WA, Nishi A, Hsieh-Wilson LC. 2006 Sulfation patterns of glycosaminoglycans encode molecular recognition and activity. Nat. Chem. Biol. 2, 467-473. (doi:10.1038/nchembio810)
201. Gallagher J. 2001 Heparan sulfate: growth control with a restricted sequence menu. J. Clin. Invest. 108, 357-361. (doi:10.1172/JCI13713)
202. Jeon O, Kang S-W, Lim H-W, Hyung Chung J, Kim B-S. 2006 Long-term and zero-order release of basic fibroblast growth factor from heparin-conjugated poly(L-lactide-co-glycolide) nanospheres and fibrin gel. Biomaterials 27, 1598-1607. (doi:10.1016/j. biomaterials.2005.08.030)
203. Yamaguchi N, Kiick K. 2005 Polysaccharide-poly(ethylene glycol) star copolymer as a scaffold for the production of bioactive hydrogels. Biomacromolecules 6, 1921-1930. (doi:10.1021/bm050003+)
204. Guo H, Cui G, Yang J, Wang C, Zhu J, Zhang L, Jiang J, Shao S. 2012 Sustained delivery of VEGF from designer self-assembling peptides improves cardiac function after myocardial infarction. Biochem. Biophys. Res. Commun. 424, 105-111. (doi:10. 1016/j.bbrc.2012.06.080)
205. Tae G, Kim Y, Choi W, Kim M, Stayton P, Hoffman A. 2007 Formation of a novel heparin-based hydrogel in the presence of heparin-binding biomolecules. Biomacromolecules 8, 1979-1986. (doi:10.1021/bm0701189)
206. Tabata Y. 1998 Protein release from gelatin matrices. Adv. Drug Deliv. Rev. 31, 287-301. (doi:10.1016/S0169-409X(97)00125-7)
207. Layman H, Sacasa M, Murphy A, Murphy A, Pham S, Andreopoulos F. 2009 Co-delivery of FGF-2 and GCSF from gelatin-based hydrogels as angiogenic therapy in a murine critical limb ischemic model. Acta Biomater. 5, 230-239. (doi:10.1016/j.actbio. 2008.07.024)
208. Kanematsu A, Marui A, Yamamoto S, Ozeki M, Hirano Y, Yamamoto M, Ogawa O, Komeda M, Tabata Y. 2004 Type I collagen can function as a reservoir of basic fibroblast growth factor. J. Control. Release Off. J. Control. Release Soc. 99, 281-292. (doi:10.1016/j.jconrel.2004.07.008)
209. Lchek M, Bayer E. 1990 Introduction to avidin-biotin technology. Methods Enzym. 184, 5-13.
210. Bogdanov AJ, Gordeeva L, Baibakov B, Margolis L, Torchilin V. 1991 Restoration of adhesive potentials of Ehrlich ascites carcinoma cells by modification of plasma membrane. J. Cell Physiol. 147, 182-190. (doi:10.1002/jcp.1041470123)
211. Bhat VD, Klitzman B, Koger K, Truskey GA, Reichert WM. 1998 Improving endothelial cell adhesion to vascular graft surfaces: clinical need and strategies. J. Biomater. Sci. Polym. Ed 9, 1117-1135. (doi:10. 1163/156856298X00686)
212. Anamelechi C, Truskey G, Reichert W. 2005 Mylar and Teflon-AF as cell culture substrates for studying endothelial cell adhesion. Biomaterials 26, 6887-6896. (doi:10.1016/j.biomaterials.2005.04.027)
213. Mathur A, Chan B, Truskey G, Reichert W. 2003 High-affinity augmentation of endothelial cell attachment: long-term effects on focal contact and actin filament formation. J. Biomed. Mater. Res. A 66, 729-737. (doi:10.1002/jbm.a.10581)
214. Mathur A, Truskey G, Reichert W. 2003 Synergistic effect of high-affinity binding and flow preconditioning on endothelial cell adhesion. J. Biomed. Mater. Res. A 64, 155-163. (doi:10. 1002/jbm.a.10403)
215. Bhat V, Truskey G, Reichert W. 1998 Fibronectin and avidin-biotin as a heterogeneous ligand system for enhanced endothelial cell adhesion. J. Biomed. Mater. Res. 41, 377-385. (doi:10.1002/(SICI)1097-4636(19980905)41:3,377::AID-JBM6.3.0.CO;2-9)
216. Tsai W, Wang M. 2005 Effects of an avidin-biotin binding system on chondrocyte adhesion and growth on biodegradable polymers. Macromol. Biosci. 5, 214-221. (doi:10.1002/mabi.200400144)
217. Tsai W, Wang M. 2005 Effect of an avidin-biotin binding system on chondrocyte adhesion, growth and gene expression. Biomaterials 26, 3141-3151. (doi:10.1016/j.biomaterials.2004.08.014)
218. Kojima N, Matsuo T, Sakai Y. 2006 Hepatic cell attachment onto biodegradable polymer surfaces without toxicity using an avidin-biotin binding system. Biomaterials 27, 4904-4910. (doi:10.1016/j.biomaterials.2006.05.026)
219. Davis ME, Hsieh PCH, Takahashi T, Song Q, Zhang S, Kamm RD, Grodzinsky AJ, Anversa P, Lee RT. 2006 Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc. Natl Acad. Sci. USA 103, 8155-8160. (doi:10.1073/pnas.0602877103)
220. Chew SY, Hufnagel TC, Lim CT, Kam WL. 2006 Mechanical properties of single electrospun drugencapsulated nanofibres. Nanotechnology 17, 3880-3891. (doi:10.1088/0957-4484/17/15/045)
221. Kim K, Luu Y, Chang C, Fang D, Hsiao B, Chu B, Hadjiargyrou M. 2004 Incorporation and controlled release of a hydrophilic antibiotic using poly(lactideco-glycolide)-based electrospun nanofibrous scaffolds. J. Control Release 98, 47-56. (doi:10. 1016/j.jconrel.2004.04.009)
222. Luu Y, Kim K, Hsiao B, Chu B, Hadjiargyrou M. 2003 Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA-PEG block copolymers. J. Control Release 341-353. (doi:10.1016/S0168-3659(03)00097-X)
223. Chew S, Wen J, Yim E, Leong K. 2005 Sustained release of proteins from electrospun biodegradable fibers. Biomacromolecules 6, 2017-2024. (doi:10. 1021/bm0501149)
224. Maretschek S, Greiner A, Kissel T. 2008 Electrospun biodegradable nanofiber nonwovens for controlled release of proteins. J. Control Release. 127, 180-187. (doi:10.1016/j.jconrel.2008.01.011)
225. Sanders EH, Kloefkorn R, Bowlin GL, Simpson DG, Wnek GE. 2003 Two-phase electrospinning from a single electrified jet: microencapsulation of aqueous reservoirs in poly(ethylene-co vinylacetate) fibers. Macromolecules 36, 3803-3805. (doi:10.1021/ma021771l)
226. Luong-Van E, Grondahl L, Chua KN, Leong KW, Nurcombe V, Cool SM. 2006 Controlled release of heparin from poly(1-caprolactone) electrospun fibers. Biomaterials 27, 2042-2050. (doi:10.1016/j. biomaterials.2005.10.028)
227. Tabata Y. 2000 The importance of drug delivery systems in tissue engineering. Pharm. Sci. Technol. Today 3, 80-89. (doi:10.1016/S1461-5347(00)00242-X)
228. Kanematsu A, Yamamoto S, Ozeki M, Noguchi T, Kanatani I, Ogawa O, Tabata Y. 2004 Collagenous matrices as release carriers of exogenous growth factors. Biomaterials 25, 4513-4520. (doi:10.1016/j.biomaterials.2003.11.035)
229. Wachiralarpphaithoon C, Iwasaki Y, Akiyoshi K. 2007 Enzyme-degradable phosphorylcholine porous hydrogels cross-linked with polyphosphoesters for cell matrices. Biomaterials 28, 984-993. (doi:10. 1016/j.biomaterials.2006.10.024)
230. Simón-Yarza T. 2012 Vascular endothelial growth factor-delivery systems for cardiac repair: an overview. Theranostics. 2, 541-552. (doi:10.7150/thno.3682)
231. Hiemstra C, Zhong Z, Van Steenbergen M, Hennink W, Feijen J. 2007 Release of model proteins and basic fibroblast growth factor from in situ forming degradable dextran hydrogels. J. Control Release 122, 71-78. (doi:10.1016/j.jconrel.2007.06.011)
232. Iwakura A, Fujita M, Kataoka K, Tambara K, Sakakibara Y, Komeda M, Tabata Y. 2003 Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Hear. Vessel. 18, 93-99. (doi:10.1007/s10380-002-0686-5)
233. Hsieh PCH, Davis ME, Gannon J, MacGillivray C, Lee RT. 2006 Controlled delivery of PDGF-BB for myocardial protection using injectable selfassembling peptide nanofibers. J. Clin. Invest. 116, 237-248. (doi:10.1172/JCI25878)
234. Fujita M et al. 2005 Efficacy of photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 in a rabbit model of chronic myocardial infarction. J. Surg. Res. 126, 27-33. (doi:10.1016/j. jss.2004.12.025)
235. Cai S, Liu Y, Zheng Shu X, Prestwich G. 2005 Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor. Biomaterials 26, 6054. (doi:10.1016/j. biomaterials.2005.03.012)
236. Hao X et al. 2007 Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc. Res. 75, 178-185. (doi:10.1016/j.cardiores.2007.03.028)
237. Ruvinov E, Leor J, Cohen S. 2010 The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials 31, 4573-4582. (doi:10.1016/j. biomaterials.2010.02.026)
238. Jeong B, Bae Y, Lee D, Kim S. 1997 Biodegradable block copolymers as injectable drug-delivery systems. Nature 388, 860-862. (doi:10.1038/42218)
239. Christman K, Fang Q, Yee M, Johnson K, Sievers R, Lee R. 2005 Enhanced neovasculature formation in ischemic myocardium following delivery of pleiotrophin plasmid in a biopolymer. Biomaterials 26, 1139-1144. (doi:10.1016/j.biomaterials.2004. 04.025)
240. Kraehenbuehl T, Ferreira L, Hayward A, Nahrendorf M, van der Vlies A, Vasile E, Weissleder R, Langer R, Hubbell J. 2011 Human embryonic stem cell-derived microvascular grafts for cardiac tissue preservation after myocardial infarction. Biomaterials 32, 1102-1109. (doi:10.1016/j.biomaterials.2010.10.005)
241. Ito Y, Hasuda H, Terai H, Kitajima T. 2005 Culture of human umbilical vein endothelial cells on immobilized vascular endothelial growth factor. J Biomed Mater Res A. 74, 659-665. (doi:10.1002/jbm.a.30360)
242. Davies N, Dobner S, Bezuidenhout D, Schmidt C, Beck M, Zisch AH, Zilla P. 2008 The dosage dependence of VEGF stimulation on scaffold neovascularisation. Biomaterials 29, 3531-3538. (doi:10.1016/j.biomaterials.2008.05.007)
243. Ennett A, Kaigler D, Mooney D. 2006 Temporally regulated delivery of VEGF in vitro and in vivo. J. Biomed. Mater. Res. A 79, 176-184. (doi:10. 1002/jbm.a.30771)
244. Fischbach C, Mooney D. 2007 Polymers for pro- and anti-angiogenic therapy. Biomaterials 28, 2069-2076. (doi:10.1016/j.biomaterials.2006.12.029)
245. Péan J, Menei P, Morel O, Montero-Menei C, Benoit J. 2000 Intraseptal implantation of NGF-releasing microspheres promote the survival of axotomized cholinergic neurons. Biomaterials 21, 2097-2101. (doi:10.1016/S0142-9612(00)00141-1)
246. Biondi M, Ungaro F, Quaglia F, Netti P. 2008 Controlled drug delivery in tissue engineering. Adv. Drug Deliv. Rev. 60, 229-242. (doi:10.1016/j.addr. 2007.08.038)
247. Lee J, Tan C, Lee S, Kim Y, Lee K. 2009 Controlled delivery of heat shock protein using an injectable microsphere/hydrogel combination system for the treatment of myocardial infarction. J. Control Release 137, 196-202. (doi:10.1016/j.jconrel. 2009.04.008)
248. Ferreira L, Gerecht S, Fuller J, Shieh H, Vunjak-Novakovic G, Langer R. 2007 Bioactive hydrogel scaffolds for controllable vascular differentiation of human embryonic stem cells. Biomaterials 28, 2706-2717. (doi:10.1016/j.biomaterials.2007. 01.021)
249. Richardson T, Peters M, Ennett A, Mooney D. 2001 Polymeric system for dual growth factor delivery. Nat. Biotechnol. 19, 1029-1034. (doi:10.1038/nbt1101-1029)
250. Holland T, Tabata Y, Mikos A. 2005 Dual growth factor delivery from degradable oligo( poly(ethylene glycol) fumarate) hydrogel scaffolds for cartilage tissue engineering. J. Control Release 101, 111-125. (doi:10.1016/j.jconrel.2004.07.004)
251. Holland T, Bodde E, Cuijpers V, Baggett L, Tabata Y, Mikos A, Jansen J. 2007 Degradable hydrogel scaffolds for in vivo delivery of single and dual growth factors in cartilage repair. Osteoarthr. Cartil. 15, 187-197. (doi:10.1016/j.joca.2006.07.006)
252. Sun Z, Zussman E, Yarin A, Wendorff J, Greiner A. 2003 Compound core-shell polymer nanofibers by co-electrospinning. Adv. Mater. 15, 1929-1932. (doi:10.1002/adma.200305136)
253. Zhang Y, Wang X, Feng Y, Li J, Lim C, Ramakrishna S. 2006 Coaxial electrospinning of (fluorescein isothiocyanate-conjugated bovine serum albumin)-encapsulated poly(1-caprolactone) nanofibers for sustained release. Biomacromolecules 7, 1049-1057. (doi:10.1021/bm050743i)
254. Wall ST, Walker JC, Healy KE, Ratcliffe MB, Guccione JM. 2006 Theoretical impact of the injection of material into the myocardium: a finite element model simulation. Circulation 114, 2627-2635. (doi:10.1161/CIRCULATIONAHA.106. 657270)
255. Landa N, Miller L, Feinberg MS, Holbova R, Shachar M, Freeman I, Cohen S, Leor J. 2008 Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 117, 1388-1396. (doi:10.1161/CIRCULATIONAHA.107.727420)
256. Davis ME, Motion JPM, Narmoneva DA, Takahashi T, Hakuno D, Kamm RD, Zhang S, Lee RT. 2005 Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 111, 442-450. (doi:10.1161/01. CIR.0000153847.47301.80)
257. Dubois G, Segers VFM, Bellamy V, Sabbah L, Peyrard S, Bruneval P, Hagge AA, Lee RT, Menasch P. 2008 Self-assembling peptide nanofibers and skeletal myoblast transplantation in infarcted myocardium. J. Biomed. Mater. Res. B, Appl. Biomater. 87, 222-228. (doi:10.1002/jbm.b.31099)
258. Lin YD et al. 2010 Intramyocardial peptide nanofiber injection improves postinfarction ventricular remodeling and efficacy of bone marrow cell therapy in pigs. Circulation 122(Suppl. 11), S132-141. (doi:10.1161/CIRCULATIONAHA.110.939512)
259. Kim JH, Jung Y, Kim SH, Sun K, Choi J, Kim HC, Park Y, Kim SH. 2011 The enhancement of mature vessel formation and cardiac function in infarcted hearts using dual growth factor delivery with selfassembling peptides. Biomaterials 32, 6080-6088.
260. Mosbach K, Ramström O. 1996 The emerging technique of molecular imprinting and its future impact on biotechnology. Biotechnology 14, 163-170. (doi:10.1038/nbt0296-163)
261. Shea K. 1994 Molecular imprinting of synthetic network polymers: the de novo synthesis of macromolecular binding and catalytic sites. Trends Polym. Sci. 2, 166-173.
262. Steinke J, Sherrington D, Dunkin I. 1995 Imprinting of synthetic polymers using molecular templates. Adv. Polym. Sci. 123, 80-125.
263. Mosbach K. 1994 Molecular imprinting. Trends Biochem. Sci. 19, 9-14. (doi:10.1016/0968-0004 (94)90166-X)
264. Wulff G, Knorr K. 2002 Stoichiometric noncovalent interaction in molecular imprinting. Bioseparation 10, 257-276. (doi:10.1023/A:1021585518592)
265. Wang H, Kobayashi T, Fujii N. 1996 Molecular imprint membranes prepared by the phase inversion precipitation technique. Langmuir 12, 4850-4856. (doi:10.1021/la960243y)
266. Wulff G. 1995 Molecular imprinting in cross-linked materials with the aid of molecular templates-a way towards artificial antibodies. Angew. Chem. Int. Ed. Engl. 34, 1812-1832. (doi:10.1002/anie. 199518121)
267. Svenson J, Nicholls IA. 2001 On the thermal and chemical stability of molecularly imprinted polymers. Anal. Chim. Acta 435, 19-24. (doi:10. 1016/S0003-2670(00)01396-9)
268. Sellergren B, Shea K. 1993 Chiral ion exchange chromatography: correlation between solute retention and a theoretical ion-exchange model using imprinted polymers. J. Chromatogr. A 654, 17-28. (doi:10.1016/0021-9673(93) 83061-V)
269. Kempe M, Mosbach K. 1995 Separation of amino acids, peptides and proteins on molecularly imprinted stationary phases. J. Chromatogr. A 691, 317-323. (doi:10.1016/0021-9673(94)00820-Y)
270. Hart B, Shea K. 2001 Synthetic peptide receptors: molecularly imprinted polymers for the recognition of peptides using peptide-metal interactions. J. Am. Chem. Soc. 123, 2072-2073. (doi:10.1021/ja005661a)
271. Cormack PAG, Mosbach K. 1999 Molecular imprinting: recent developments and the road ahead. React. Funct. Polym. 41, 115-124. (doi:10. 1016/S1381-5148(99)00024-3)
272. Cristallini C, Ciardelli G, Barbani N, Giusti P. 2004 Acrylonitrile-acrylic acid copolymer membrane imprinted with uric acid for clinical uses. Macromol. Biosci. 4, 31-38. (doi:10.1002/mabi.200300026)
273. Silvestri D, Borrelli C, Giusti P, Cristallini C, Ciardelli G. 2005 Polymeric devices containing imprinted nanospheres: a novel approach to improve recognition in water for clinical uses. Anal. Chim. Acta 542, 3-13. (doi:10.1016/j.aca.2004.12.005)
274. Rosellini E, Barbani N, Giusti P, Ciardelli G, Cristallini C. 2010 Novel bioactive scaffolds with fibronectin recognition nanosites based on molecular imprinting technology. J. Appl. Polym. Sci. 118, 3236-3244. (doi:10.1002/app.32622)
275. Rosellini E, Barbani N, Giusti P, Ciardelli G, Cristallini C. 2010 Molecularly imprinted nanoparticles with recognition properties towards a laminin H-Tyr-Ile-Gly-Ser-Arg-OH sequence for tissue engineering applications. Biomed. Mater. 5, 11. (doi:10.1088/1748-6041/5/6/065007)
276. Rachkova A, Norihiko M. 2001 Towards molecularly imprinted polymers selective to peptides and proteins. The epitope approach. Biochim. Biophys. Acta 1544, 255-266. (doi:10.1016/S0167-4838(00)00226-0)
277. Akiyama SK, Yamada KM. 1987 Fibronectin. Adv. Enzymol. Relat. Areas Mol. Biol. 59, 1-57. (doi:10. 1002/9780470123058.ch1)
278. Humphries MJ, Obara M, Olden K, Yamada KM. 1989 Role of fibronectin in adhesion, migration, and metastasis. Cancer Invest. 7, 373-393. (doi:10. 3109/07357908909039866)
279. Larsen M, Artym VV, Green JA, Yamada KM. 2006 The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr. Opin. Cell. Biol. 18, 463-471. (doi:10.1016/j.ceb.2006.08.009)
280. Colognato H, Yurchenco PD. 2000 Form and function: the laminin family of heterotrimers. Dev. Dyn. 218, 213-234. (doi:10.1002/(SICI)1097-0177(200006)218:2,213::AID-DVDY1.3.0.CO;2-R)
281. Miner JH, Yurchenco PD. 2004 Laminin functions in tissue morphogenesis. Annu. Rev. Cell Dev. Biol. 20, 255-284. (doi:10.1146/annurev.cellbio.20.010403.094555)